1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends


  • September 2019
  • 13 pages
  • ID: 5817155
  • Format: PDF
  • By Pharma Intelligence


Table of Contents

Drug Overview
Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in adolescents and young adults from 10 years through to 25 years of age in the US, and in individuals two months of age and older in the EU. Bexsero contains three surface-exposed recombinant proteins: factor H binding protein, Neisseria adhesin A, and Neisseria heparin-binding antigen. It also includes New Zealand strain outer membrane vesicles. The antibodies generated after immunization with Bexsero target the aforementioned surface proteins present on the outer membrane vesicles.
Bexsero is one of two serotype B meningococcal vaccines approved in the EU and US markets. Following its incorporation into the US, Italian, and UK vaccination schedules throughout 2015 and 2016, Bexsero’s sales have risen rapidly in these markets, and continue to grow with the gradual uptake in key risk groups. However, in France, Germany, and Spain, Bexsero is only reimbursed for very small populations at high risk of IMD due to uncertainties regarding its real-world benefit and poor cost effectiveness. It is unlikely that Bexsero will be incorporated into the immunization schedules of these EU markets unless GlaxoSmithKline offers substantial discounts and gathers real-world data to clearly demonstrate a reduction in the serogroup B IMD burden, ideally with an accompanying herd immunity benefit by reducing nasal carriage. In the long term, GlaxoSmithKline intends to position its pipeline vaccine MenABCW-135Y (pentavalent meningococcal conjugate vaccine) as a successor to Bexsero and Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine) in persons aged ?10 years, although the combined vaccine’s launch is not expected until 2022.
In 2018, GlaxoSmithKline initiated a Phase III study for Bexsero in US infants aged six weeks to 12 months, and given the high cost and high coverage rates seen for meningococcal serotype B (MenB) vaccines in the infant population, an indication expansion for use in infants would be a lucrative next step for Bexsero in the US. In Italy and the UK, the introduction of MenB vaccination into the routine infant immunization schedule drove significant sales growth.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Smallpox - Pipeline Review, H2 2019

Smallpox - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Smallpox - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H2 2019, provides an overview of the Smallpox (Infectious Disease) ...

Dilated Cardiomyopathy - Pipeline Review, H2 2019

Dilated Cardiomyopathy - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Dilated Cardiomyopathy - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2019, provides ...

Integrin Beta 7 - Pipeline Review, H2 2019

Integrin Beta 7 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Integrin Beta 7 - Pipeline Review, H2 2019SummaryIntegrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on